Familial hypercholesterolemia: PCSK9 InsLEU genetic variant and prediabetes/diabetes risk.
about
Effect of LDL cholesterol, statins and presence of mutations on the prevalence of type 2 diabetes in heterozygous familial hypercholesterolemiaBiology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies.Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia.Using Human 'Experiments of Nature' to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors.
P2860
Familial hypercholesterolemia: PCSK9 InsLEU genetic variant and prediabetes/diabetes risk.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Familial hypercholesterolemia: ...... and prediabetes/diabetes risk.
@en
Familial hypercholesterolemia: ...... and prediabetes/diabetes risk.
@nl
type
label
Familial hypercholesterolemia: ...... and prediabetes/diabetes risk.
@en
Familial hypercholesterolemia: ...... and prediabetes/diabetes risk.
@nl
prefLabel
Familial hypercholesterolemia: ...... and prediabetes/diabetes risk.
@en
Familial hypercholesterolemia: ...... and prediabetes/diabetes risk.
@nl
P2093
P1476
Familial hypercholesterolemia: ...... and prediabetes/diabetes risk.
@en
P2093
Alexis Baass
Robert Dufour
Yascara G Luna Saavedra
P304
786-793.e1
P356
10.1016/J.JACL.2015.08.005
P407
P577
2015-08-28T00:00:00Z